Selecta Biosciences is a clinical-stage biotechnology company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.

Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications with the potential for improved efficacy and safety profiles.

Fully synthetic vaccine manufacturing offers a number of compelling benefits, including flexible modular vaccine design and reduced development cost and time. While production and regulatory processes for biologically produced vaccines are often complex and time consuming, Selecta's SVP™ vaccines can be developed and approved faster for the following reasons:

• Self assembly technology enables SVP™ design variations that are analogous to structure–activity relation analyses used in small molecule drug discovery.
• Modular building blocks enable robust and rapid product development.
• Demonstrated scalability is based upon use of established pharmaceutical unit operations and processes.   

Selecta's SVP™ platform technology enables diverse vaccine applications and designs. The company has created two distinct products: targeted Synthetic Vaccine Particles (tSVP™) and targeted tolerogenic Synthetic Vaccine Particles (t²SVP™).

targeted Synthetic Vaccine Particles (tSVP™) activate immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles can target humoral or cellular pathways of the immune system. Examples for applications include cancer, infectious diseases, allergies, and addiction.

targeted tolerogenic Synthetic Vaccine Particles (t²SVP™) are designed to induce antigen-specific immune tolerance. Examples for applications include autoimmune diseases, allergies, and transplant rejection.

Building on the company's novel approach, Selecta's product candidates have the potential to become first-in-class or best-in-class therapeutics to treat and prevent diseases. The company's lead program entered human clinical trials in 2011, and the company is committed to rapidly advancing its broad pipeline of product candidates.

Selecta Biosciences is based in Watertown, Massachusetts, USA.